MOUNTAIN VIEW, Calif., May 28, 2015 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL), today announced that on May 20, 2015, plaintiff Jeffrey Nelson voluntarily dismissed his action, Nelson v. Omnicell, Inc., et al., 15-CV-01280, brought before the Northern District Court of California, without prejudice, as to all defendants. Mr. Nelson purported to file a class action lawsuit on behalf of all Omnicell shareholders who purchased stock between May 2, 2014 and March 2, 2015.
With the dismissal of the Nelson lawsuit, no pending class action lawsuits are outstanding, following the resolution of Omnicell's recent whistleblower investigation that had postponed the filing of the Company's 2014 Annual Report on Form 10-K until March 30, 2015.
Since 1992, Omnicell (NASDAQ: OMCL) has been creating new efficiencies to improve patient care, anywhere it is delivered. Omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire healthcare continuum— from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home.
More than 3,000 customers worldwide have utilized Omnicell Automation and Analytics solutions to increase operational efficiency, reduce errors, deliver actionable intelligence and improve patient safety. Omnicell Medication Adherence solutions, including its MTS Medication Technologies brand, provide innovative medication adherence packaging solutions to help reduce costly hospital readmissions. In addition, these solutions enable approximately 6,000 institutional and retail pharmacies worldwide to maintain high accuracy and quality standards in medication dispensing and administration while optimizing productivity and controlling costs.
SOURCE Omnicell, Inc.